newsfilter
← Latest News
ACCESS Newswire·

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerabilityTrial progressing efficiently, Cohort 4 open for enrollment SEATTLE, WA